Akari Therapeutics Accelerates ADC Development with WuXi XDC Partnership
Event summary
- Akari Therapeutics CEO Abizer Gaslightwala discussed the strategic partnership with WuXi XDC in a Virtual Investor interview on April 9, 2026.
- The partnership is expected to accelerate the IND filing timeline for AKTX-101 to late 2026.
- WuXi XDC's involvement extends beyond traditional CDMO engagement, supporting Akari's ADC development and reducing execution risk.
- Akari highlighted the broader ADC market trends and potential partnering opportunities.
The big picture
The partnership with WuXi XDC validates Akari's novel PH1 spliceosome-modulating payload platform and accelerates its lead program, AKTX-101. This collaboration comes amid increasing deal activity in the ADC market, positioning Akari to leverage broader industry trends and potential partnering opportunities. The strategic alliance reduces execution risk and strengthens Akari's development capabilities, setting a clearer path toward first-in-human clinical studies.
What we're watching
- Development Timeline
- Whether Akari can maintain the accelerated IND filing timeline for AKTX-101 through late 2026.
- Market Positioning
- How the partnership with WuXi XDC will position Akari within the rapidly evolving ADC landscape.
- Partnering Opportunities
- The pace at which Akari can identify and secure additional strategic partnerships or collaborations.
Related topics